AVICOR was established in 2005 based on a patent portfolio covering the application of chemically modified solid surfaces for chemical microarray production and affinity bead preparation. Avicor is a service provider with clients from Europe and US big pharma and medium size companies.

Avicor offers fully-integrated contract research, discovery and development services including drug discovery, target identification, and analytics.

Primary activities:

  • Drug discovery
  • Hit discovery
  • Analytical measurements (LC/MS, NMR, etc. )
  • Custom synthesis
  • Target identification (AviLink technology)

AVICOR has a diverse small molecule library of 60000 member and a Chemical Department with medicinal chemistry capabilities to synthesize novel scaffolds and to optimize lead molecules.

Different screening technologies were developed to

  • identify novel hit molecules
  • to determine molecular target of a drug candidate with unknown mechanism of action
  • to detect whether a drug is a possible target for a G-protein coupled receptor or ion channel
  • to decide whether a drug candidate has an off-target effect

These screening technologies are based on classical biochemical screening using fluorescence or luminescence read-out, or by using a label-free technology platform with our proprietary surface chemistry, and novel bead technology for affinity chromatography and protein mass-spectrographic analysis.

Avicor is a leading drug discovery and development company offering fully-integrated contract research and manufacturing services including medicinal chemistry, hit discovery, lead optimization, in vitro pharmacology, screen development and target identification.